Substancedefinition-nucleicacid-mipomersen-example

FHIR CI-Build

This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions

Example SubstanceDefinition/mipomersen (Narrative)

Responsible Owner: Biomedical Research and Regulation Work Group

Standards Status: Informative

Compartments: No defined compartments

This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile SubstanceDefinition.

Generated Narrative: SubstanceDefinition mipomersen

identifier: http://example.europa.eu/fhir/SMSId/MIPO78654S

status: Active

classification: Nucleic Acid

domain: Human use

description:

Mipomersen sodium — a synthetic second-generation 2'-methoxyethyl antisense oligonucleotide that inhibits the molecular target apolipoprotein B-100 (APOB-100). 20-mer phosphorothioate-linked sequence with 2'-MOE wing chemistry.

Codes

Code

MIPO78654S

name
name: Mipomersen Sodium
preferred: true
language: English
Officials

- Authority Status

* INN Active

nucleicAcid
sequenceType: Complete
numberOfSubunits: 1
oligoNucleotideType: Antisense oligonucleotide
subunit
subunit: 1
sequence: GCCUCAGTCTGCTTCGCACC
length: 20
fivePrime: Guanosine
threePrime: Cytidine
linkage
connectivity:
Substances

- Concept

* Phosphorothioate linkage
residueSite: 1-19
sugar
Substances

- Concept

* 2'-O-(2-methoxyethyl) ribose
residueSite: 1-5,16-20
sugar
Substances

- Concept

* 2'-deoxyribose
residueSite: 6-15
gene
sequenceOrigin: Human
Genes

- Concept

* apolipoprotein B

Relationships

SubstanceDefinition[x]

Type

Interaction

apolipoprotein B-100

Therapeutic target

Inhibition

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.